The FDA has released over 200 complete response letters as part of its initiative to increase agency transparency and modernize regulatory communication. However, this release includes limitations and does not provide unrestricted access to all correspondence. This partial transparency marks a shift in FDA policies, aiming to provide stakeholders with more insight into drug application rejections while balancing regulatory and privacy considerations.